Status:
COMPLETED
Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing Spondylitis
Lead Sponsor:
Instituto de Medicina Molecular João Lobo Antunes
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Rheumatoid Arthritis
Bone Resorption
Eligibility:
All Genders
18-90 years
Brief Summary
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are characterized by chronic systemic inflammation and share common pathogenic pathways. In both diseases, cytokines like TNF (tumor necrosis ...
Detailed Description
Objectives: 1. Assess the influence of immune system cells in the modulation of bone turnover in patients with RA, AS and healthy donors (Task 2). 2. Analyze the osteoclast precursors and their diffe...
Eligibility Criteria
Inclusion
- Patients with RA diagnosis (according to the revised American Rheumatism Association criteria, 1988) and AS diagnosis (according to the European Spondyloarthropathy Study Group criteria, 1991) followed up in the Rheumatology and Bone and Metabolic Diseases Department of Hospital de Santa Maria (HSM) will be recruited for this study. Patients have to have active RA (Disease Activity Score 28 (DAS28)\>3.2) or active AS (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)\>4).
Exclusion
- Inactive disease
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT01417455
Start Date
January 1 2012
End Date
May 1 2015
Last Update
March 21 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto de Medicina Molecular
Lisbon, Portugal, 1600-145